Lichtenstein, G. R., Rogler, G., Ciorba, M. A., Su, C., Chan, G., Pedersen, R. D., . . . Panés, J. (2020). Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis.
Citação norma ChicagoLichtenstein, Gary R., et al. "Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program." Inflamm Bowel Dis 2020.
Citação norma MLALichtenstein, Gary R., et al. "Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program." Inflamm Bowel Dis 2020.